Minimizing tacrolimus decreases the risk of new-onset diabetes mellitus after liver transplantation

Table 3 Univariate analysis of risk factors for new-onset diabetes mellitus after liver transplantation

Clinical factor	HR	95%CI	P value
Recipient characteristics
Elder recipient (age > 50 yr)	1.568	1.096-2.245	0.014
Male recipient gender	0.690	0.414-1.150	0.155
Child-Pugh (A/B/C)	0.985	0.788-1.232	0.895
MELD Score	1.107	0.997-1.037	0.088
BMI ≥ 25 pre-LT	1.616	1.100-2.373	0.014
Hypertension pre-LT	4.458	2.058-9.659	< 0.001
Dyslipidaemia pre-LT	2.064	1.201-3.549	0.009
Hepatitis B virus disease	0.955	0.632-1.443	0.828
Hepatitis C virus disease	0.699	0.098-5.007	0.722
Alcoholic cirrhosis	2.307	1.076-4.948	0.032
Tumors	0.961	0.676-1.304	0.822
With Rapamycin	1.168	0.744-1.761	0.459
With MMF	0.979	0.690-1.387	0.903
High mean cTAC (cTAC ≥ 5.89 ng/mL)	8.709	5.873-12.915	< 0.001
BMI ≥ 25 post-LT	1.345	0.927-1.951	0.119
Hypertension post-LT	1.278	0.808-2.021	0.294
Dyslipidaemia post-LT	2.014	1.429-2.838	< 0.001
CKD post-LT	1.140	0.925-1.405	0.218
AR post-LT	1.701	1.056-2.742	0.029
CR post-LT	2.068	1.050-4.074	0.036
Donor characteristics
Donor age at LT (per year)	0.994	0.975-1.015	0.590
Male donor gender	1.202	0.766-1.886	0.423
Donor type (LDLT)	0.859	0.581-1.270	0.446

LT: Liver transplantation; MELD: Model for end-stage liver disease; MMF: Mycophenolate mofetil; cTAC: Tacrolimus trough concentration; CKD: Chronic kidney disease; AR: Acute rejection; CR: Chronic rejection; BMI: Body mass index; LDLT: Living donor liver transplantation.